Benzinga | Oct 23, 2020 06:07AM EDT

RBC Capital Initiates Coverage On CRISPR Therapeutics with Sector Perform Rating, Announces Price Target of $110

RBC Capital initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform rating and announces Price Target of $110.